Will Palantir Crash?
AI and data analytics software major Palantir (NASDAQ:PLTR) has been…
Sell
36
EXAS Quote, Financials, Valuation and Earnings
Last price:
$53.28
Seasonality move
:
8.8%
Day range:
$52.45 - $54.52
52-week range:
$39.97 - $72.83
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.49x
P/B ratio:
4.19x
Volume:
2.8M
Avg. volume:
3M
1-year change:
27.27%
Market cap:
$10.1B
Revenue:
$2.8B
EPS (TTM):
-$5.51
Analysts' Opinion
-
Consensus RatingExact Sciences has received a consensus rating of Buy. The company's average rating is a Buy based on 18 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $68.86, Exact Sciences has an estimated upside of 29.19% from its current price of $53.30.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $54.00 representing 100% downside risk from its current price of $53.30.
Fair Value
-
According to the consensus of 22 analysts, Exact Sciences has 29.19% upside to fair value with a price target of $68.86 per share.
EXAS vs. S&P 500
-
Over the past 5 trading days, Exact Sciences has underperformed the S&P 500 by -2.61% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Exact Sciences does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Exact Sciences has grown year-over-year revenues for 38 quarters straight. In the most recent quarter Exact Sciences reported revenues of $706.8M.
Earnings Growth
-
Exact Sciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Exact Sciences reported earnings per share of -$0.54.
Enterprise value:
11.6B
EV / Invested capital:
2.46x
Price / LTM sales:
3.49x
EV / EBIT:
--
EV / Revenue:
4.10x
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
59.70x
Price / Operating cash flow:
50.88x
Enterprise value / EBITDA:
448.54x
Gross Profit (TTM):
$2B
Return On Assets:
-16.22%
Net Income Margin (TTM):
-36.06%
Return On Equity:
-35.57%
Return On Invested Capital:
-19.08%
Operating Margin:
-12.7%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $2.2B | $2.5B | $2.8B | $637.5M | $706.8M | |
| Gross Profit | $1.5B | $1.8B | $2B | $446.3M | $500.5M | |
| Operating Income | -$477.7M | -$239.6M | -$166.7M | -$102.2M | -$89.8M | |
| EBITDA | -$314.8M | -$3.7M | -$792.2M | -$47.9M | -$38.1M | |
| Diluted EPS | -$2.92 | -$1.32 | -$5.51 | -$0.60 | -$0.54 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.8B | $1.2B | $1.1B | $1.1B | $1.4B | |
| Total Assets | $6.7B | $6.5B | $6.3B | $6.4B | $5.7B | |
| Current Liabilities | $628.9M | $481M | $367.4M | $685.1M | $502.5M | |
| Total Liabilities | $3.1B | $3.2B | $3.2B | $3.2B | $3.3B | |
| Total Equity | $3.6B | $3.3B | $3.1B | $3.1B | $2.4B | |
| Total Debt | $2.2B | $2.2B | $2.4B | $2.4B | $2.3B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$88M | $112M | $323.7M | -$82.3M | $30.8M | |
| Cash From Investing | $111.4M | -$204.7M | -$305.2M | -$171.4M | -$34.4M | |
| Cash From Financing | $207.3M | $23.2M | -$21.3M | -$3M | -$256.2M | |
| Free Cash Flow | -$298.2M | -$20.5M | $194.1M | -$120M | -$365K | |
EXAS
Sector
Market Cap
$10.1B
$32.3M
Price % of 52-Week High
73.18%
46.89%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
27.27%
-37.62%
Beta (5-Year)
0.977
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$54.57
200-day SMA
Sell
Level
$56.03
Bollinger Bands (100)
Buy
Level
45.06 - 55.12
Chaikin Money Flow
Buy
Level
77.9M
20-day SMA
Sell
Level
$55.82
Relative Strength Index (RSI14)
Sell
Level
46.16
ADX Line
Sell
Level
20.4
Williams %R
Buy
Level
-86.3563
50-day SMA
Buy
Level
$50.91
MACD (12, 26)
Buy
Level
0.55
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
168.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.7888)
Sell
CA Score
(Annual)
Level (-1.2625)
Buy
Beneish M-Score
(Annual)
Level (-3.3643)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (0.7452)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Stock Forecast FAQ
In the current month, EXAS has received 18 Buy ratings 4 Hold ratings, and 0 Sell ratings. The EXAS average analyst price target in the past 3 months is $68.86.
-
Where Will Exact Sciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Exact Sciences share price will rise to $68.86 per share over the next 12 months.
-
What Do Analysts Say About Exact Sciences?
Analysts are divided on their view about Exact Sciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Exact Sciences is a Sell and believe this share price will drop from its current level to $54.00.
-
What Is Exact Sciences's Price Target?
The price target for Exact Sciences over the next 1-year time period is forecast to be $68.86 according to 22 Wall Street analysts, 18 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is EXAS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Exact Sciences is a Buy. 18 of 22 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of EXAS?
You can purchase shares of Exact Sciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Exact Sciences shares.
-
What Is The Exact Sciences Share Price Today?
Exact Sciences was last trading at $53.28 per share. This represents the most recent stock quote for Exact Sciences. Yesterday, Exact Sciences closed at $53.30 per share.
-
How To Buy Exact Sciences Stock Online?
In order to purchase Exact Sciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Target’s Dividend Worth Buying?
Retail giant Target (NYSE:TGT) has been through an extremely volatile…
Where Will AST SpaceMobile Be In 5 Years?
Ever tried to send a text from the Nevada desert…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
37
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
49
RGC alert for Jun 17
Regencell Bioscience Holdings [RGC] is down 89.92% over the past day.
Sell
16
VEON alert for Jun 17
VEON [VEON] is up 4.61% over the past day.
Buy
64
INOD alert for Jun 17
Innodata [INOD] is up 13.78% over the past day.
